Rapamycin, also called sirolimus, is an exogenous prescription macrolide mTOR inhibitor studied in transplant medicine, lymphangioleiomyomatosis, immune-aging, respiratory-infection outcomes, topical skin markers, exercise adaptation, healthy-aging research, and animal lifespan studies (FDA) (Research).
Rapamycin is one of the most studied pharmacological compounds in experimental aging biology because it extends lifespan in several mouse studies, including late-life treatment studies, but no published human trial has demonstrated that rapamycin extends human lifespan (Research) (Review). Human evidence is strongest in approved or disease-specific contexts such as kidney-transplant rejection prophylaxis and lymphangioleiomyomatosis, while healthy-aging evidence remains limited and focused on safety, immune response, respiratory infections, exercise adaptation, topical skin markers, and healthspan-related outcomes (FDA) (Research). This report lists study-reported quantities as research context only and provides no recommendations, no personal-use instructions, and no anti-aging regimen guidance.
Ingredient Identity
- Official name(s): Rapamycin; sirolimus.
- Synonyms: Rapamune, sirolimus, rapamycin.
- Classification: Macrolide compound; mTOR inhibitor; prescription immunosuppressive medicine (FDA).
- CAS number: 53123-88-9.
- Endogenous vs exogenous: Exogenous; rapamycin is not a normal human metabolite and was originally isolated from a microorganism (Review).
- Regulatory status: Prescription medicine in the United States and European Union for defined medical indications, not an approved anti-aging or longevity therapy (FDA) (EMA).
Ingredient Snapshot
- Classification: Rapamycin is a macrolide mTOR inhibitor used clinically as an immunosuppressive prescription medicine (FDA).
- Endogenous vs exogenous status: Rapamycin is exogenous and is not produced by the human body as a normal nutrient or metabolite (Review).
- Primary human research domains: Human research includes transplant medicine, lymphangioleiomyomatosis, immune function in older adults, respiratory-infection outcomes, topical skin markers, exercise adaptation, reproductive-aging protocols, periodontal-aging protocols, and exploratory healthy-aging outcomes (Research) (Research) (Research).
- Common study formats: Human studies include randomized controlled trials, pilot trials, disease-specific clinical trials, topical intervention studies, trial registrations, and reviews of healthy-aging evidence (Research) (Research) (Review).
- Pharmacokinetic characterization status: Sirolimus pharmacokinetics are clinically characterized in prescribing information, but healthy-aging exposure strategies remain investigational and are not established as approved medical practice (FDA).
- Regulatory context: In the United States, Rapamune is FDA-labeled for kidney-transplant rejection prophylaxis in patients aged 13 years or older and for lymphangioleiomyomatosis, not for anti-aging or longevity (FDA).
- Evidence maturity: Animal lifespan evidence is strong, while human anti-aging evidence is limited/mixed because human studies have not demonstrated lifespan extension (Research) (Review).
Introduction
Rapamycin is a biologically active compound that binds FKBP12 and changes signaling through mTORC1, a protein complex that helps cells decide whether to prioritize growth, protein production, and biosynthesis or maintenance processes such as autophagy (Review). The term mTOR means mechanistic target of rapamycin, and it refers to a central nutrient-sensing protein kinase that responds to amino acids, insulin-related signals, energy availability, oxygen, and stress (Review).
Rapamycin attracts attention in anti-aging research because mouse studies report lifespan extension and because mTORC1 sits near several aging-related processes, including autophagy, protein production, cellular senescence, immune function, metabolism, and inflammation (Research) (Review). Human studies have examined narrower outcomes such as vaccine response, respiratory infections, exercise adaptation, topical skin markers, disease-specific lung outcomes, and healthspan metrics rather than direct lifespan extension (Research) (Review).
This article is informational only, describes rapamycin as a biochemical substance studied in human and animal research, and does not provide medical or dosing advice.
Quick Summary
- Rapamycin and sirolimus refer to the same active prescription compound, a macrolide mTOR inhibitor used in defined medical settings rather than an approved anti-aging therapy (FDA).
- Rapamycin has strong animal lifespan evidence, including a late-life mouse study where age at 90% mortality increased by 14% in females and 9% in males, but no human trial has demonstrated lifespan extension (Research) (Review).
- Human healthy-aging research includes PEARL, a 48-week trial in 114 adults aged 50–85 using 5 mg/week and 10 mg/week rapamycin arms, but PEARL measured safety and healthspan metrics rather than survival (Research).
- A small older-adult pilot trial used 1 mg/day rapamycin in 25 generally healthy adults aged 70–95 and reported feasibility but no clear broad improvements in clinical labs, cognition, physical performance, or immune parameters (Research).
- The RAPA-EX-01 exercise trial used 6 mg/week sirolimus for 13 weeks in 40 sedentary adults aged 65–85 and did not find enhanced exercise-related functional gains (Research).
- Human immune-aging studies with rapalogs or related mTOR inhibitors reported vaccine-response or infection-related signals, but those endpoints do not establish whole-body rejuvenation or human life extension (Research) (Research).
- Important safety concerns include immunosuppression, infection risk, delayed wound healing, lipid changes, mouth ulcers, lung-related warnings, reproductive cautions, and medicine interactions (FDA).
Human Research Findings by Condition
Aging and Longevity Research
Human aging research on rapamycin is best described as aging-adjacent healthspan research, not demonstrated human life-extension research, because completed trials have measured safety, body composition, pain, immune parameters, physical function, cognition, and biomarkers rather than survival (Research) (Review). The strongest quantitative lifespan-extension evidence remains animal-based, especially mouse studies with dietary rapamycin exposure and survival endpoints (Research).
Key human study
Dose studied: 1 mg rapamycin daily or placebo.
Population: 25 generally healthy adults aged 70–95; 11 rapamycin and 14 control participants completed at least 8 weeks and were included in analysis.
Duration: At least 8 weeks for analyzed participants.
Researchers tested whether daily rapamycin was feasible and tolerable in an older human cohort while measuring immune parameters, physical performance, cognitive outcomes, and clinical laboratory measures (Research). The trial was small, and it did not show clear broad improvements in clinical labs, cognition, physical performance, or immune parameters (Research).
Result: Human clinical study reported no clear effect
Evidence strength: Emerging
Study source: (Research)
Additional human study
Dose studied: 5 mg compounded rapamycin once weekly, 10 mg compounded rapamycin once weekly, or placebo.
Population: 114 healthy adults aged 50–85.
Duration: 48 weeks.
The PEARL trial studied low-dose intermittent rapamycin in healthy adults and measured safety and healthspan metrics rather than lifespan extension (Research). Female participants in the 10 mg/week group had statistically significant lean-tissue mass changes at 24 and 48 weeks compared with placebo, while males in the 5 mg/week group had a small HbA1c increase at 48 weeks without significant glucose or insulin changes in the cited report (Research).
Result: Human clinical study reported a modest improvement
Evidence strength: Emerging
Study source: (Research)
Immune System
Human immune-system research has examined whether partial mTOR inhibition can improve immune responses in older adults without reproducing the degree of immunosuppression used in transplant medicine (Research) (Research). Findings are aging-relevant because vaccine response and infection vulnerability change with age, but immune endpoints do not prove lifespan extension (Review).
Key human study
Dose studied: RAD001/everolimus 0.5 mg daily, 5 mg weekly, or 20 mg weekly.
Population: Older adult volunteers.
Duration: 6 weeks, followed by an influenza-vaccine response assessment after study-drug discontinuation.
Researchers studied RAD001, also known as everolimus, which is a rapamycin-related compound called a rapalog (Research). RAD001 enhanced influenza-vaccine response by about 20% at relatively well-tolerated doses, and dose details in the study included 0.5 mg daily, 5 mg weekly, and 20 mg weekly regimens (Research).
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Limited
Study source: (Research)
Additional human study
Dose studied: Low-dose TORC1-inhibitor therapy; the accessible PubMed abstract identifies a low-dose RAD001 plus BEZ235 combination but does not display the full numeric arm structure.
Population: 264 older adults.
Duration: 6 weeks.
A phase 2a randomized placebo-controlled trial studied TORC1 inhibition in older adults and reported enhanced immune-function measures plus a significant decrease in infection rates for a year after study-drug initiation (P = 0.001) (Research). The study supports immune-aging research but does not show that rapamycin itself extends human lifespan (Research).
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Limited
Study source: (Research)
Infection
Human infection research has examined respiratory-infection outcomes and antiviral gene-expression responses in older adults using mTOR-pathway inhibitors, including RTB101 and combinations with everolimus (Research). The evidence is mixed because phase 2b findings were more favorable than later phase 3 clinical endpoint findings (Research).
Key human study
Dose studied: Part 1 arms included RTB101 5 mg once daily, RTB101 10 mg once daily, or placebo; Part 2 arms included RTB101 10 mg once daily, RTB101 10 mg twice daily, RTB101 10 mg plus everolimus 0.1 mg daily, or placebo.
Population: 652 older adults in the phase 2b program.
Duration: 16 weeks.
The phase 2b RTB101 trial tested respiratory-infection outcomes in older adults and reported fewer laboratory-confirmed respiratory tract infections in the 10 mg once-daily RTB101 group compared with pooled placebo (34/176, 19% vs 50/180, 28%; OR 0.601, P = 0.02) (Research). RTB101 is not rapamycin, and this infection endpoint is not a lifespan-extension endpoint (Research).
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Limited
Study source: (Research)
Additional human study
Dose studied: RTB101 10 mg once daily for 16 weeks in the phase 3 ClinicalTrials.gov record.
Population: Adults aged 65 years or older in a phase 3 respiratory-illness trial.
Duration: 16 weeks.
The phase 3 RTB101 trial was designed to test prevention of clinically symptomatic respiratory illness in older adults and used 10 mg daily RTB101 for 16 weeks in the experimental arm (Research). The broader published program reported that phase 3 did not reduce clinically symptomatic respiratory illness, which limits confidence in translating phase 2b infection findings (Research).
Result: Human clinical studies reported mixed findings
Evidence strength: Mixed
Study source: (Research)
Respiratory and Lung Health
Respiratory and lung research includes strong disease-specific human evidence for sirolimus in lymphangioleiomyomatosis, a rare lung disease associated with inappropriate mTOR signaling (Research). This evidence is clinically meaningful for LAM but should not be generalized to healthy longevity (FDA).
Key human study
Dose studied: Sirolimus adjusted to maintain trough levels between 5 and 15 ng/mL under clinical monitoring.
Population: 89 patients with lymphangioleiomyomatosis and moderate lung impairment; 46 sirolimus and 43 placebo.
Duration: 12 months of treatment plus 12 months of observation.
The MILES trial found that the FEV1 slope was −12±2 mL/month in the placebo group and 1±2 mL/month in the sirolimus group during the treatment period (P < 0.001) (Research). Lung-function decline resumed after treatment stopped, which suggests a treatment-dependent disease effect rather than proof of systemic anti-aging (Research).
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: (Research)
Kidney Health
Kidney-related research has focused on angiomyolipomas, which are benign tumors that can occur in tuberous sclerosis complex or lymphangioleiomyomatosis (Research). These findings support human mTOR-pathway relevance in selected disease contexts but do not establish anti-aging effects in healthy kidneys (Research).
Key human study
Dose studied: Target serum sirolimus ranges included 1–5 ng/mL in one sporadic LAM patient and escalation to 10–15 ng/mL in most other patients after imaging-based review.
Population: Patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.
Duration: 12 months treatment plus follow-up to 24 months.
In a nonrandomized open-label study, mean angiomyolipoma volume at 12 months was 53.2±26.6% of baseline (P < 0.001) and at 24 months was 85.9±28.5% of baseline (P = 0.005) (Research). The study supports disease-specific mTOR targeting but does not show healthy-aging benefit (Research).
Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)
Muscle Health
Muscle-health research is important because mTORC1 supports muscle-protein synthesis and exercise adaptation, so inhibiting mTORC1 may interact differently with aging biology than with training response (Review). A recent human exercise trial did not support the idea that sirolimus enhances short-term exercise adaptation in older adults (Research).
Key human study
Dose studied: 6 mg sirolimus once weekly or matched placebo.
Population: 40 sedentary adults aged 65–85; mean age 72.2 years; 47.5% female.
Duration: 13 weeks.
The RAPA-EX-01 trial tested once-weekly sirolimus during a home-based exercise program in older adults (Research). Sirolimus did not enhance functional gains from exercise and may have modestly attenuated some short-term functional improvements in sensitivity analyses (Research).
Result: Human clinical study reported no clear effect
Evidence strength: Emerging
Study source: (Research)
Beauty and Skin Health
Skin research has examined topical rapamycin as a local intervention for aging-related skin markers rather than as a systemic longevity therapy (Research). This evidence is relevant to local senescence biology, but it is limited in size and does not establish whole-body anti-aging effects (Research).
Key human study
Dose studied: 10 μM rapamycin, described as approximately 0.001%, with 0.5 cc applied to the dorsal hand every 24–48 hours or daily in the study description.
Population: Adults aged 40 years or older in an exploratory topical skin study.
Duration: 6–8 months.
The topical rapamycin study treated human skin with rapamycin cream on one hand and vehicle control on the other hand (Research). The study reported reduced p16INK4A and increased collagen VII markers, but the findings were local skin-marker outcomes rather than systemic longevity outcomes (Research).
Result: Human clinical study reported a modest improvement
Evidence strength: Emerging
Study source: (Research)
Reproductive Health
Human reproductive-aging research is currently represented mainly by registered trial protocols rather than completed peer-reviewed efficacy results. This evidence should be labeled as protocol-stage evidence unless or until completed results are published (Research).
Key human study
Dose studied: Dose/exposure not visible in the accessible ClinicalTrials.gov source view; the registry describes “low-dose rapamycin.”
Population: Women in an ovarian-aging study context.
Duration: Protocol-stage study; completed published efficacy results were not available in the verified source view.
The VIBRANT / ovarian-aging trial registration describes a prospective, randomized, double-blind, placebo-controlled pilot study assessing low-dose rapamycin for ovarian aging (Research). The registry is a protocol source, so it should not be treated as completed evidence of efficacy or safety (Research).
Result: Human evidence remains limited or inconclusive
Evidence strength: Emerging
Study source: (Research)
Oral Health
Human oral-health research for rapamycin is emerging and includes registered periodontal-aging work and observational/off-label oral-health profiling rather than mature randomized outcome evidence. This area is relevant to aging because periodontal disease increases with age, but available human evidence should be treated as early (Research) (Research).
Key human study
Dose studied: Dose/exposure not visible in the accessible RAPID source view.
Population: Older adults with periodontal disease in a registered clinical-trial context.
Duration: Registered-trial context; completed results not available in the accessible source view.
The University of Washington RAPID source describes an FDA-approved trial evaluating rapamycin for periodontal disease in older adults (Research). The RAPID source is a trial information page rather than a completed peer-reviewed efficacy report, so the evidence remains protocol-stage for this report (Research).
Result: Human evidence remains limited or inconclusive
Evidence strength: Emerging
Study source: (Research)
Additional human study
Dose studied: Dose details not reported in the accessible PubMed abstract/source view.
Population: Off-label rapamycin users in an oral-health profiling study.
Duration: Observational / secondary-analysis context.
A PubMed-indexed study profiled oral-health outcomes among off-label rapamycin users and reported oral-health observations including mouth-sore patterns (Research). Because this was not a randomized anti-aging efficacy trial and dosing details were not visible in the accessible abstract/source view, the evidence is observational and limited (Research).
Result: Observational human studies reported an association
Evidence strength: Observational
Study source: (Research)
Dosage & Study Snapshot (Research Context)
This section lists study-reported exposure quantities because they are part of the published research record. These are research exposures, not recommendations, personal-use instructions, or anti-aging regimen guidance.
0.5 mg/day everolimus and 5 mg/week everolimus:
The RAD001/everolimus influenza-vaccine trial studied older adults for 6 weeks and included low-dose daily and weekly everolimus arms, with vaccination response measured after a drug-free interval (Research). A review of mTOR inhibitors reports that 0.5 mg once daily and 5 mg once weekly everolimus were well tolerated and significantly improved influenza-vaccine response in older adults (Review). This is a rapalog immune-aging study, not a sirolimus lifespan-extension study.
Result: Statistically significant improvement
Evidence strength: Limited
Notes / limitations: Everolimus is related to rapamycin but is not identical to sirolimus.
1 mg/day rapamycin:
A placebo-controlled pilot trial randomized 25 generally healthy adults aged 70–95 to 1 mg/day rapamycin or placebo, and 11 rapamycin and 14 control participants completed at least 8 weeks for analysis (Research). The study evaluated feasibility, safety, immune measures, cognition, physical performance, and self-rated health (Research). It did not show clear broad improvements across clinical, cognitive, functional, or immune outcomes.
Result: Neutral overall findings
Evidence strength: Emerging
Notes / limitations: Small pilot study; not powered to establish anti-aging efficacy.
5 mg/week rapamycin:
The PEARL trial included a 5 mg/week compounded rapamycin arm in healthy adults aged 50–85 over 48 weeks (Research). The study reported a small HbA1c increase in males in the 5 mg cohort at 48 weeks but no significant glucose or insulin changes in the cited report (Research). PEARL measured safety and healthspan metrics rather than survival.
Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: Healthspan metrics are not human lifespan-extension outcomes.
6 mg/week sirolimus:
The RAPA-EX-01 trial assigned 40 sedentary adults aged 65–85 to 6 mg sirolimus once weekly or matched placebo during a 13-week home exercise program (Research). The trial found that sirolimus did not enhance functional gains from exercise and may have modestly attenuated some short-term improvements in sensitivity analyses (Research). This study is important because mTORC1 supports muscle adaptation, so pathway inhibition may have different effects during exercise than during other contexts (Review).
Result: No clear effect
Evidence strength: Emerging
Notes / limitations: Exercise adaptation is a functional endpoint, not a longevity endpoint.
10 mg/week rapamycin:
The PEARL trial included a 10 mg/week compounded rapamycin arm in healthy adults over 48 weeks (Research). Female participants in the 10 mg/week group had significant lean-tissue mass improvements compared with placebo at 24 weeks and 48 weeks in the cited report (Research). The trial did not test whether rapamycin extends human lifespan.
Result: Modest improvement
Evidence strength: Emerging
Notes / limitations: Sex-specific body-composition findings require replication.
10 mg/day RTB101 and RTB101 + everolimus 0.1 mg/day:
The RTB101 phase 2b program included RTB101 5 mg once daily, RTB101 10 mg once daily, RTB101 10 mg twice daily, and RTB101 10 mg plus everolimus 0.1 mg daily arms over 16 weeks in older adults (Research). The 10 mg once-daily RTB101 group had fewer laboratory-confirmed respiratory tract infections than pooled placebo in the phase 2b analysis, but later phase 3 clinical endpoint results were not confirmatory (Research) (Research). RTB101 is an mTOR-pathway inhibitor, not rapamycin itself.
Result: Mixed findings
Evidence strength: Mixed
Notes / limitations: Infection findings differed across trial phases.
10 μM / 0.001% topical rapamycin:
A topical skin-aging study used 10 μM rapamycin, described as approximately 0.001%, applied locally to human skin for 6–8 months with 0.5 cc applied to the dorsal hand in the study protocol (Research). Researchers reported local changes in markers associated with senescence and skin aging, including p16INK4A and collagen VII outcomes (Research). These are local dermatologic findings and do not show systemic longevity effects.
Result: Modest improvement
Evidence strength: Emerging
Notes / limitations: Topical local effects should not be generalized to whole-body aging.
5–15 ng/mL sirolimus trough range in LAM:
The MILES trial maintained sirolimus trough levels between 5 and 15 ng/mL in patients with lymphangioleiomyomatosis and measured lung function over 12 months of treatment plus 12 months of observation (Research). The sirolimus group had an FEV1 slope of 1±2 mL/month compared with −12±2 mL/month in placebo during active treatment (Research). This is disease-specific monitored exposure, not healthy-aging evidence.
Result: Statistically significant improvement
Evidence strength: Moderate
Notes / limitations: Disease-specific monitored trough ranges should not be interpreted as longevity ranges.
1–5 ng/mL and 10–15 ng/mL sirolimus serum ranges in angiomyolipoma research:
A study of sirolimus for angiomyolipoma in tuberous sclerosis complex or sporadic lymphangioleiomyomatosis reported serum target ranges including 1–5 ng/mL in one sporadic LAM patient and escalation to 10–15 ng/mL in most others based on imaging review (Research). Mean angiomyolipoma volume at 12 months was 53.2±26.6% of baseline and at 24 months was 85.9±28.5% of baseline (Research). The findings show disease-specific mTOR effects but do not establish anti-aging benefit.
Result: Modest improvement
Evidence strength: Limited
Notes / limitations: Tumor-volume outcomes are not longevity outcomes.
4.7 ppm, 14 ppm, and 42 ppm dietary rapamycin in mice:
A mouse dose-response study used 4.7 ppm, 14 ppm, and 42 ppm rapamycin in food starting at 9 months in UM-HET3 mice (Research). Blood concentrations across 4.7, 14, and 42 ppm were 7, 16, and 80 ng/mL in females and 6, 9, and 23 ng/mL in males, showing substantial sex differences in exposure at the same dietary concentrations (Research). Lifespan effects were dose- and sex-dependent, so animal exposure cannot be converted directly into human dosing logic (Research).
Result: Statistically significant improvement
Evidence strength: Strong animal evidence
Notes / limitations: Animal ppm exposure is not a human regimen.
Late-life mouse exposure starting at 600 days:
A landmark mouse study fed rapamycin to genetically heterogeneous mice beginning at 600 days of age and reported increased age at 90% mortality of 14% in females and 9% in males (Research). The same paper emphasized that rapamycin feeding extended mouse lifespan even when treatment began late in life (Research). This is the strongest type of longevity evidence in the rapamycin field, but it is not human evidence.
Result: Statistically significant improvement
Evidence strength: Strong animal evidence
Notes / limitations: Mouse survival extension does not prove human lifespan extension.
42 ppm and time-limited mouse regimens:
A late-life mouse regimen study compared continuous, 3-month, and 1 month on / 1 month off rapamycin patterns using 42 ppm dietary rapamycin starting at 20 months (Research). Continuous exposure increased survival in both sexes, 3-month treatment benefited males, and intermittent exposure benefited both sexes but was less effective than continuous exposure in females (Research). This study shows that timing and schedule matter in mice.
Result: Statistically significant improvement
Evidence strength: Strong animal evidence
Notes / limitations: Schedule-dependent mouse outcomes are not human dosing guidance.
Key Takeaways from Human Research
- Human rapamycin research includes published dose/exposure information in several aging-adjacent trials, including 1 mg/day, 5 mg/week, 6 mg/week, and 10 mg/week study contexts, but no human study has demonstrated lifespan extension (Research) (Research) (Research).
- The strongest human evidence is disease-specific, especially lymphangioleiomyomatosis and TSC/LAM angiomyolipoma research, where monitored sirolimus exposure produced disease-relevant outcomes (Research) (Research).
- Healthy-aging evidence remains exploratory because PEARL measured safety and healthspan metrics over 48 weeks, not human survival (Research).
- Immune-aging trials suggest that mTOR-pathway inhibition can affect vaccine response or respiratory-infection outcomes, but the findings involve rapalogs or RTB101 and do not prove rapamycin extends lifespan (Research) (Research).
- Exercise research does not show that sirolimus improves short-term exercise adaptation in older adults, which matters because mTORC1 is involved in muscle-protein synthesis and training response (Research) (Review).
- Animal lifespan studies remain central to rapamycin’s anti-aging reputation, but mouse dose-response and sex-difference data show why animal results cannot be converted directly into human anti-aging conclusions (Research) (Research).
Origin & Natural Occurrence
Rapamycin was originally isolated from a microorganism associated with soil from Rapa Nui, also known as Easter Island, and later became clinically developed as sirolimus (Review). It is not a vitamin, mineral, amino acid, or normal human metabolite (Review).
Rapamycin is not meaningfully obtained from foods in the way nutrients such as magnesium, vitamin C, or polyphenols are obtained from diet (FDA). In research and clinical settings, rapamycin/sirolimus is handled as a pharmacological compound with prescription uses rather than as a dietary ingredient (FDA).
How It Behaves in the Body
Rapamycin works by changing how cells interpret nutrient and growth signals through the mTOR pathway (Review). A useful plain-language explanation is that mTORC1 acts like a cellular “growth permission system”: when nutrients and growth signals are abundant, mTORC1 supports protein production, growth, and biosynthesis (Review).
The term mTOR means mechanistic target of rapamycin, and it refers to a protein kinase that changes the activity of other proteins by adding phosphate groups (Review). A protein kinase acts like a molecular switch-controller, because phosphate changes can turn cellular processes up or down (Review).
mTOR forms two major complexes called mTORC1 and mTORC2 (Review). mTORC1 is more directly sensitive to rapamycin and regulates protein production, lipid production, nutrient sensing, and autophagy, while mTORC2 influences cell survival, internal cell structure, and aspects of glucose metabolism (Review).
Autophagy means cellular recycling, a process in which cells break down damaged proteins and worn-out structures so their parts can be reused or cleared (Review). mTORC1 normally restrains parts of autophagy, so mTORC1 inhibition can permit more autophagic activity in some cellular contexts (Review).
Cellular senescence means a state in which cells stop dividing but remain metabolically active (Research). Some senescent cells release inflammatory molecules called the senescence-associated secretory phenotype, or SASP, and persistent mTORC1 signaling has been linked with senescence biology (Research).
Rapamycin is not a direct epigenome editor, because it does not target a chosen DNA sequence or directly rewrite a selected methylation mark (Review). Any epigenetic effects are indirect and occur through broader changes in nutrient sensing, metabolism, autophagy, inflammatory signaling, and gene-expression programs (Review).
Absorption & Delivery Formats
Oral immediate-release: Oral tablets and oral solution are established clinical formats in prescribing information, and these formats are used in medical contexts where safety warnings, therapeutic monitoring, and drug interactions matter (FDA).
Oral extended-release: Extended-release rapamycin is not the main evidence base in the aging-adjacent trials summarized here, because completed human aging-adjacent studies used defined oral rapamycin, sirolimus, everolimus, or RTB101 study designs rather than consumer-style supplement formats (Research) (Research).
Sublingual: Sublingual rapamycin is not a major evidence base in the verified human aging-adjacent studies summarized here. Claims about sublingual delivery would require formulation-specific human pharmacokinetic evidence, which was not part of the verified source set for this report.
Transdermal / topical: Topical rapamycin has been studied locally in human skin-aging research using 10 μM / approximately 0.001% rapamycin for 6–8 months, but those findings are local skin-marker findings rather than systemic longevity evidence (Research).
Injectable / IV: Injectable anti-aging protocols are not part of the human evidence base summarized here. Rapamycin/sirolimus clinical use is governed by approved medical indications and prescribing information, not anti-aging injection protocols (FDA).
Quick Facts at a Glance
Onset reported:
Human aging-adjacent studies measure outcomes over weeks or months rather than immediate effects, with examples including 6 weeks for RAD001 immune-vaccine research, at least 8 weeks for the older-adult rapamycin pilot, 13 weeks for RAPA-EX-01, and 48 weeks for PEARL (Research) (Research) (Research) (Research).
Time to peak (Tmax):
Clinical labeling reports sirolimus pharmacokinetic details for approved medical contexts, and these values are used for medical interpretation rather than anti-aging efficacy claims (FDA). The clinical importance for this report is that exposure varies by formulation, food, metabolism, and interacting medicines rather than being a simple anti-aging marker (FDA).
Half-life (t½):
Sirolimus has clinically relevant persistence in the body, and prescribing information treats concentration monitoring and drug interactions as important in approved medical contexts (FDA). Half-life information does not establish a safe or effective anti-aging regimen (FDA).
Typical duration:
Human aging-adjacent rapamycin or rapalog studies include 6 weeks, at least 8 weeks, 13 weeks, 16 weeks, 24 weeks in registered everolimus aging research, and 48 weeks in PEARL (Research) (Research) (Research) (Research) (Research).
Absorption routes studied:
The main human evidence base involves oral exposure, including rapamycin/sirolimus, everolimus, and RTB101, plus local topical skin exposure in one exploratory skin-aging study (Research) (Research). Topical exposure is local, whereas oral exposure can affect systemic pathways and therefore has different safety implications (Research) (FDA).
Formulation differences:
Rapamycin, sirolimus, everolimus, and RTB101 should not be treated as interchangeable because they differ by compound, formulation, pharmacology, target profile, and regulatory status (Research) (Research) (Review).
Variability drivers:
Exposure and effect may vary by age, sex, disease state, immune status, formulation, interacting medicines, and metabolism (FDA). Mouse dose-response research also shows sex-related blood-level differences, with 42 ppm producing 80 ng/mL in females and 23 ng/mL in males in one study, which underscores why animal exposure cannot be directly translated to humans (Research).
Tolerance / adaptation:
There is no established healthy-aging tolerance model showing that rapamycin benefits increase or risks disappear over time (Review). In LAM, lung-function benefit appeared treatment-dependent because decline resumed after sirolimus was stopped, showing that disease effects may not persist after discontinuation (Research).
Evidence strength snapshot:
Animal lifespan evidence is strong, human disease-specific evidence is meaningful in selected conditions, and direct human anti-aging evidence is limited/mixed because human trials have not demonstrated lifespan extension (Research) (Research) (Review).
Other Physiological Contexts Studied (If Applicable)
- Mouse lifespan: Rapamycin extended lifespan in genetically heterogeneous mice when treatment began at 600 days, increasing age at 90% mortality by 14% in females and 9% in males (Research).
- Mouse dose-response and sex differences: Dietary rapamycin at 4.7 ppm, 14 ppm, and 42 ppm produced sex-dependent blood concentrations and lifespan effects in UM-HET3 mice (Research).
- Late-life mouse regimen comparison: Continuous and intermittent 42 ppm rapamycin regimens beginning at 20 months produced sex- and schedule-dependent survival effects in mice (Research).
- Epigenetic clocks: A marmoset study evaluated DNA-methylation age in a rapamycin context, while a later review reported no detectable rapamycin effect on next-generation epigenetic clocks in the intervention evidence it reviewed (Research) (Review).
- Oral health: Human oral-health evidence remains early, with an FDA-approved periodontal trial information page and observational off-label oral-health profiling rather than mature randomized efficacy results (Research) (Research).
Safety, Interactions & Regulation
Sirolimus is an immunosuppressive prescription medicine, and FDA labeling states that Rapamune is indicated for prophylaxis of organ rejection in kidney-transplant patients aged 13 years or older and for lymphangioleiomyomatosis (FDA). FDA labeling does not list anti-aging or longevity as approved indications (FDA).
FDA labeling warns that immunosuppression can increase susceptibility to infection and possible development of lymphoma and other malignancies (FDA). FDA labeling also includes warnings or precautions related to impaired wound healing, hyperlipidemia, decline in renal function, proteinuria, latent viral infections, interstitial lung disease or noninfectious pneumonitis, embryo-fetal toxicity, male infertility, immunization considerations, and drug interactions (FDA).
Interaction concerns are important because sirolimus exposure can be affected by strong CYP3A4 and P-gp inhibitors or inducers (FDA). FDA labeling also notes cannabidiol interaction considerations, which is relevant because consumer products may affect drug exposure in clinically important ways (FDA).
Population cautions are especially relevant for people with infection risk, wound-healing concerns, transplant status, lung disease, metabolic disease, reproductive considerations, vaccine timing considerations, or interacting medicines (FDA). These are clinical-risk categories rather than wellness categories (FDA).
In the European Union, EMA describes Rapamune as a medicine used to prevent rejection of a newly transplanted kidney in adults at low to moderate immunological risk and as available in oral solution and tablet forms (EMA). EMA does not describe Rapamune as an approved anti-aging or longevity medicine (EMA).
Evidence Overview
Rapamycin has a split evidence profile: animal lifespan evidence is strong and quantitative, human disease-specific evidence is clinically meaningful in selected conditions, and human healthy-aging evidence remains limited/mixed because completed human trials have measured intermediate outcomes rather than lifespan. Mouse studies report survival effects, including a late-life study starting at 600 days with 14% and 9% increases in age at 90% mortality in females and males, while human trials report study exposures such as 1 mg/day, 5 mg/week, 6 mg/week, and 10 mg/week in aging-adjacent designs without showing human survival extension (Research) (Research) (Research) (Research). Confidence is not higher because human trials are short relative to aging, heterogeneous in endpoints, and not designed to determine lifespan extension (Review).
The strongest human clinical evidence is not broad anti-aging evidence. In lymphangioleiomyomatosis, sirolimus stabilized FEV1 decline during active treatment using monitored trough levels of 5–15 ng/mL, and in TSC/LAM angiomyolipoma research, sirolimus reduced angiomyolipoma volume to 53.2±26.6% of baseline at 12 months (Research) (Research). These outcomes show that mTOR inhibition can be clinically powerful in specific diseases, but they do not show that healthy adults live longer (Research).
Human immune-aging evidence is notable but still indirect. RAD001/everolimus improved influenza-vaccine response by about 20% in older adults, and RTB101 phase 2b data showed fewer laboratory-confirmed respiratory tract infections in one dose arm, but phase 3 respiratory illness outcomes were not confirmatory (Research) (Research) (Research). Vaccine-response and infection endpoints are useful aging-adjacent outcomes but are not whole-body rejuvenation or lifespan-extension endpoints (Review).
Healthy-aging trials remain exploratory. PEARL studied 114 adults aged 50–85 for 48 weeks using 5 mg/week and 10 mg/week rapamycin arms, while the older-adult feasibility trial used 1 mg/day in adults aged 70–95, and RAPA-EX-01 used 6 mg/week sirolimus for 13 weeks in adults aged 65–85 (Research) (Research) (Research). These studies provide quantitative human data, but they do not provide a human lifespan-extension percentage (Review).
Epigenetic-clock evidence remains cautious. A marmoset study assessed rapamycin in relation to DNA-methylation age, while a later review reported no detectable rapamycin effect on next-generation epigenetic-clock evidence it evaluated (Research) (Review). Epigenetic clocks are biomarkers, not direct evidence that function, disease risk, or lifespan improved (Review).
Evidence Confidence Classification
Limited / Mixed is the best overall human evidence classification for rapamycin as an anti-aging or longevity intervention because animal lifespan evidence is strong, but human trials have not demonstrated lifespan extension (Research) (Review).
This classification reflects a split between preclinical and clinical evidence: mouse studies report quantitative lifespan extension, while human trials focus on narrower outcomes such as healthspan metrics, immune response, respiratory infections, LAM, skin markers, exercise adaptation, oral-health protocols, and safety (Research) (Research) (Review).
Human confidence would increase with larger randomized trials that measure clinically meaningful outcomes over longer periods, such as preserved physical function, durable immune competence, lower incidence of multiple age-related diseases, acceptable long-term safety, and eventually survival-related endpoints (Review).
Similar Ingredients & Comparators
Similar supplement-style ingredients often discussed in nutrient-sensing or aging research:
- Spermidine
- Resveratrol
- Nicotinamide riboside
- NMN
- Alpha-ketoglutarate
- Urolithin A
- Fisetin
- Quercetin
- GlyNAC
- Omega-3 fatty acids
- Berberine
Medical / pharma comparator categories:
- Rapalogs, such as everolimus
- Selective mTORC1 inhibitors
- Catalytic mTOR kinase inhibitors
- AMPK-pathway drugs
- Senolytic investigational drug categories
- Transplant immunosuppressants
- Oncology mTOR-pathway inhibitors
Combination Context
Sirolimus + exercise:
Sirolimus was studied with a home-based exercise program because mTOR signaling influences muscle adaptation and aging-related function (Research). In 40 sedentary adults aged 65–85, 6 mg/week sirolimus for 13 weeks did not enhance exercise-related functional gains and may have modestly attenuated some improvements in sensitivity analyses (Research).
Everolimus + influenza vaccination:
Everolimus/RAD001 was studied before influenza vaccination because older adults often have weaker vaccine responses, a feature of immune aging (Research). The study used 0.5 mg daily, 5 mg weekly, and 20 mg weekly RAD001 arms and reported about 20% improved influenza-vaccine response, but this does not prove systemic rejuvenation or lifespan extension (Research).
RTB101 + everolimus:
The RTB101 phase 2b respiratory-infection program included an arm using RTB101 10 mg plus everolimus 0.1 mg daily over 16 weeks in older adults (Research). The phase 2b signal was not matched by the later phase 3 clinical symptomatic respiratory-illness endpoint, so this combination context remains mixed (Research) (Research).
Sirolimus + disease-specific monitoring:
In LAM, sirolimus was studied with therapeutic trough monitoring to maintain 5–15 ng/mL during a 12-month treatment period (Research). This combination of drug exposure and clinical monitoring is disease-specific and should not be generalized to anti-aging use (Research).
FAQ
1. What is rapamycin?
Rapamycin, also called sirolimus, is a prescription macrolide compound that inhibits part of the mTOR pathway (FDA). It is used in defined medical settings such as kidney-transplant rejection prophylaxis and lymphangioleiomyomatosis, not as an FDA-approved anti-aging medicine (FDA). It is studied in aging because mTORC1 regulates growth, metabolism, autophagy, and cellular maintenance (Review).
2. What does mTOR mean?
mTOR means mechanistic target of rapamycin (Review). It is a protein kinase, meaning an enzyme that changes the activity of other proteins by adding phosphate groups (Review). mTOR helps cells respond to nutrients, hormones, energy status, oxygen, and stress (Review).
3. What is mTORC1?
mTORC1 is one of the main protein complexes built around mTOR (Review). A protein complex is a group of proteins that work together like a molecular machine. mTORC1 supports protein production, cell growth, lipid production, and suppression of autophagy when nutrients and growth signals are abundant (Review).
4. What is mTORC2?
mTORC2 is another mTOR-containing protein complex (Review). It influences cell survival, internal cell structure, and aspects of glucose metabolism (Review). Rapamycin more directly affects mTORC1, but prolonged exposure can affect mTORC2 in some contexts (Review).
5. Why is rapamycin discussed in anti-aging research?
Rapamycin is discussed in anti-aging research because it extends lifespan in multiple mouse studies and targets mTORC1, a pathway linked with nutrient sensing, autophagy, senescence, and metabolism (Research) (Review). The strongest quantitative lifespan evidence is animal evidence, not human evidence (Research). Human trials have not shown that rapamycin extends human lifespan (Review).
6. Has rapamycin extended lifespan in humans?
No published human trial has demonstrated that rapamycin extends human lifespan (Review). Human studies have measured narrower outcomes such as healthspan metrics, vaccine response, infection outcomes, skin markers, physical function, safety, and disease-specific endpoints (Research) (Research). Animal lifespan findings are important but cannot be assumed to apply directly to humans (Review).
7. Are there human rapamycin studies with published dose information?
Yes, several human aging-adjacent studies publish dose or exposure information as research methodology (Research) (Research) (Research). Published examples include 1 mg/day rapamycin, 5 mg/week rapamycin, 10 mg/week rapamycin, and 6 mg/week sirolimus in controlled human study contexts (Research) (Research) (Research). These are study-reported quantities, not recommendations or personal-use instructions.
8. What is the strongest lifespan evidence?
The strongest lifespan evidence is in mice (Research). A landmark study found that rapamycin started at 600 days increased age at 90% mortality by 14% in females and 9% in males (Research). Another mouse study reported dose- and sex-dependent effects using 4.7 ppm, 14 ppm, and 42 ppm dietary rapamycin (Research).
9. What human research is most relevant to aging?
The most relevant human aging-adjacent research includes PEARL, the older-adult feasibility trial, RAPA-EX-01, rapalog vaccine-response studies, RTB101 infection studies, topical skin-marker research, reproductive-aging protocols, and periodontal-aging protocols (Research) (Research) (Research) (Research). These studies examine pieces of aging biology rather than direct lifespan extension (Review).
10. What did PEARL show?
PEARL studied 114 healthy adults aged 50–85 for 48 weeks using 5 mg/week and 10 mg/week rapamycin arms plus placebo (Research). The report found significant lean-tissue mass changes in women in the 10 mg/week group and a small HbA1c increase in males in the 5 mg/week group (Research). PEARL did not measure or prove human lifespan extension (Research).
11. What did the older-adult feasibility trial show?
The older-adult feasibility trial studied 1 mg/day rapamycin or placebo in 25 generally healthy adults aged 70–95 (Research). 11 rapamycin and 14 control participants completed at least 8 weeks and were included in analysis (Research). The study found feasibility but no clear broad improvement in clinical labs, cognition, physical performance, or immune parameters (Research).
12. What did the exercise trial show?
The RAPA-EX-01 exercise trial studied 6 mg/week sirolimus or placebo in 40 sedentary adults aged 65–85 during a 13-week home exercise program (Research). Sirolimus did not enhance exercise-related functional gains and may have modestly attenuated some improvements in sensitivity analyses (Research). This is important because mTORC1 supports muscle adaptation as well as aging-related cellular growth signaling (Review).
13. What are the best-supported human uses?
The best-supported human uses are approved or disease-specific medical contexts, not general anti-aging (FDA). In LAM, sirolimus stabilized FEV1 decline during treatment with monitored trough levels of 5–15 ng/mL (Research). In TSC/LAM angiomyolipoma research, sirolimus reduced angiomyolipoma volume to 53.2±26.6% of baseline at 12 months (Research).
14. Where is evidence mixed or limited?
Evidence is mixed or limited for healthy-aging outcomes, respiratory-infection prevention, exercise enhancement, epigenetic-clock change, reproductive aging, and oral-health aging protocols (Research) (Research) (Review) (Research). Phase 2b infection findings were more favorable than phase 3 clinical endpoint findings (Research) (Research). Exercise research did not show improved functional gains in older adults (Research).
15. What is autophagy?
Autophagy is cellular recycling (Review). Cells use autophagy to break down damaged proteins and worn-out structures so their components can be reused or cleared (Review). mTORC1 normally suppresses parts of autophagy, so mTORC1 inhibition can permit more recycling activity in some cells (Review).
16. What is cellular senescence?
Cellular senescence is a state in which a cell stops dividing but remains biologically active (Research). Some senescent cells release inflammatory signals called SASP, short for senescence-associated secretory phenotype (Research). Persistent mTORC1 signaling is linked with several senescence-related processes (Research).
17. Does rapamycin remove senescent cells?
Rapamycin is not generally classified as a senolytic, meaning a compound that removes senescent cells. It may influence senescence signaling and SASP-related biology, but that is not the same as clearing senescent cells (Research). This distinction matters because suppressing inflammatory signals is different from eliminating the cells that produce them.
18. Is rapamycin an epigenetic rejuvenation therapy?
Current evidence does not establish rapamycin as a human epigenetic rejuvenation therapy (Review). A marmoset study assessed rapamycin in relation to DNA-methylation age, while a later review found no detectable rapamycin effect on next-generation epigenetic-clock evidence it evaluated (Research) (Review). Epigenetic clocks are biomarkers and do not by themselves prove clinical rejuvenation (Review).
19. How quickly does rapamycin act?
There is no established onset for anti-aging benefit in humans (Review). Human aging-adjacent studies measure outcomes after defined research periods such as 6 weeks, at least 8 weeks, 13 weeks, 16 weeks, or 48 weeks (Research) (Research) (Research) (Research). These timelines are research designs rather than proof of when an anti-aging effect begins.
20. What affects absorption and variability?
Absorption and exposure can be affected by formulation, food, metabolism, interacting medicines, disease context, and individual biology (FDA). FDA labeling highlights drug-interaction concerns involving CYP3A4 and P-gp pathways (FDA). Mouse studies also show sex-related differences in blood exposure at the same dietary concentrations, which reinforces that exposure is not simple even within one species (Research).
21. Is tolerance reported?
There is no established healthy-aging tolerance pattern showing that rapamycin becomes safer or more beneficial over time (Review). In LAM, treatment effects appeared treatment-dependent because lung-function decline resumed after sirolimus was stopped (Research). Long-term healthy-aging risk–benefit remains unresolved (Review).
22. Why do studies disagree?
Studies may disagree because they use different compounds, populations, endpoints, durations, formulations, and outcome definitions (Review). For example, RTB101 phase 2b laboratory-confirmed respiratory-infection findings were more favorable than later phase 3 clinically symptomatic respiratory-illness findings (Research) (Research). Aging research is especially difficult because short-term biomarkers or immune outcomes do not always predict long-term clinical outcomes (Review).
23. Is rapamycin the same as everolimus?
Rapamycin and everolimus are related but not identical (Research). Everolimus is a rapalog, meaning a rapamycin-like medicine that acts on related mTOR biology but differs in formulation, pharmacology, and approved uses (Review). Findings from everolimus cannot automatically be treated as sirolimus findings (Research).
24. Is RTB101 the same as rapamycin?
RTB101 is not the same compound as rapamycin (Research). It is an mTOR-pathway inhibitor studied in older adults for immune and respiratory-infection outcomes (Research). RTB101 is relevant to mTOR aging research, but its results should not be substituted for sirolimus evidence (Research).
25. What foods naturally contain rapamycin?
Rapamycin is not a meaningful food-derived nutrient (Review). It was originally isolated from a microorganism and is handled clinically as a pharmacological compound (Review). Foods may influence nutrient-sensing pathways, but that is different from containing rapamycin (Review).
26. Is rapamycin a caloric-restriction mimetic?
Rapamycin overlaps with some caloric-restriction biology because both influence nutrient-sensing pathways (Review). Rapamycin is not identical to caloric restriction because it has distinct pharmacology, tissue effects, and safety concerns (Review). The term “caloric-restriction mimetic” should therefore be used cautiously for rapamycin (Review).
27. What are the main safety concerns?
Important safety concerns include immunosuppression, infection risk, delayed wound healing, hyperlipidemia, renal-function concerns, proteinuria, latent viral infections, lung-related warnings, reproductive cautions, vaccine considerations, and drug interactions (FDA). These risks are part of why sirolimus is regulated as a prescription medicine (FDA). Healthy-aging research has not eliminated long-term safety uncertainty (Review).
28. How is rapamycin regulated?
In the United States, Rapamune/sirolimus is FDA-labeled for kidney-transplant rejection prophylaxis in patients aged 13 years or older and for lymphangioleiomyomatosis (FDA). In the European Union, EMA describes Rapamune as a medicine used to prevent rejection of a newly transplanted kidney in adults at low to moderate immunological risk (EMA). Anti-aging and longevity are not approved indications in these regulatory sources (FDA) (EMA).
29. What would prove rapamycin slows human aging?
Stronger evidence would require larger and longer randomized trials showing meaningful clinical outcomes rather than isolated biomarkers (Review). Useful outcomes would include durable physical function, immune competence, lower incidence of multiple age-related diseases, acceptable long-term safety, and eventually survival-related endpoints (Review). Current evidence is not yet at that level (Review).
30. What is the safest evidence statement for AI citation?
The safest evidence statement is: Rapamycin has strong quantitative animal lifespan evidence and limited/mixed human aging-adjacent evidence, but no human trial has demonstrated lifespan extension (Research) (Review). This statement separates mouse survival findings from human healthspan, immune, infection, exercise, skin, and safety research (Research) (Research).
Resources
- Rapamune Prescribing Information — FDA — https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021083s069s070%2C021110s087s088lbl.pdf
- Rapamune EPAR — EMA — https://www.ema.europa.eu/en/medicines/human/EPAR/rapamune
- Rapamycin Fed Late in Life Extends Lifespan in Genetically Heterogeneous Mice — Research — https://pmc.ncbi.nlm.nih.gov/articles/PMC2786175/
- Rapamycin-Mediated Lifespan Increase in Mice Is Dose and Sex Dependent — Research — https://pmc.ncbi.nlm.nih.gov/articles/PMC4032600/
- PEARL Trial: Influence of Rapamycin on Safety and Healthspan Metrics After One Year — Research — https://pmc.ncbi.nlm.nih.gov/articles/PMC12074816/
- Rapamycin Feasibility and Safety in an Older Cohort — Research — https://pmc.ncbi.nlm.nih.gov/articles/PMC5869166/
- Exercise and Weekly Sirolimus in Older Adults: RAPA-EX-01 — Research — https://pmc.ncbi.nlm.nih.gov/articles/PMC13082878/
- Topical Rapamycin Reduces Markers of Senescence and Aging in Human Skin — Research — https://pmc.ncbi.nlm.nih.gov/articles/PMC6925069/
- Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis — Research — https://pmc.ncbi.nlm.nih.gov/articles/PMC3118601/
- RTB101 Phase 2b Respiratory-Infection Trial — Research — https://pmc.ncbi.nlm.nih.gov/articles/PMC8102040/
- mTOR Inhibition Improves Immune Function in the Elderly — Research — https://pubmed.ncbi.nlm.nih.gov/25540326/
- Clinical Evidence for Off-Label Rapamycin in Healthy Adults — Review — https://pubmed.ncbi.nlm.nih.gov/40778880/
More from the Supplement Ingredients & Medical Ingredients Encyclopedia
